Resources from the same session
Discussion
Presenter: Elise Kohn
Session: Best of abstracts session
Resources:
Slides
Webcast
Live Q&A and discussion
Presenter: All Speakers
Session: Best of abstracts session
Resources:
Webcast
Rucaparib vs chemotherapy in patients with advanced, relapsed ovarian cancer and a deleterious BRCA mutation: Efficacy and safety from ARIEL4, a randomized phase 3 study
Presenter: Rebecca Kristeleit
Session: Best of abstracts session
Resources:
Slides
Webcast
Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase III trial of bevacizumab (bev)-containing therapy +/- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC)
Presenter: Kathleen Moore
Session: Best of abstracts session
Resources:
Slides
Webcast
Discussion
Presenter: Susana Banerjee
Session: Best of abstracts session
Resources:
Slides
Webcast
Live Q&A and discussion
Presenter: All Speakers
Session: Best of abstracts session
Resources:
Webcast
Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation
Presenter: Andres Maria Poveda Velasco
Session: Best of abstracts session
Resources:
Slides
Webcast